U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

Stocks in Europe ended Monday's session slightly higher, as investors reacted to more disappointing economic news out of the ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Health insurers such as UnitedHealth Group and Cigna also recovered some of their recent losses following public controversy about industry practices in the wake of the assassination of UnitedHealth ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The study met its main goal, but those watching closely had hoped for an average result of at least 25% weight loss.

Europe's STOXX 600 ended the day slightly up, driven by a surge in Novo Nordisk shares that helped the healthcare sector. Low trading volumes characterized the day due to holiday anticipation, while ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 but keeps an Outperform rating on the shares. The ...